Get them here FREE<\/a>.<\/p>\nThe central argument is that the Novo Nordisk deal removes a significant legal overhang and positions Hims & Hers as a platform offering branded, generic, and compounded products. That pivot, JPMorgan argues, legitimizes the GLP-1 business and widens the addressable market.<\/p>\n
Company Snapshot <\/p>\n
Hims & Hers closed fiscal 2025 with $2.35 billion in revenue, up 59% year over year, with Q4 revenue of $617.82 million and adjusted EPS of $0.08. Subscriber monetization improved, with monthly revenue per subscriber reaching $83.<\/p>\n
Management guided full-year 2026 revenue of $2.7 billion to $2.9 billion and adjusted EBITDA of $300 million to $375 million. Hims & Hers CEO Andrew Dudum is also leaning on M&A, including the Eucalyptus acquisition (ARR north of $450 million) to push into Australia and Japan.<\/p>\n
Why the Move Matters Now <\/p>\n
The timing matters because the Novo Nordisk relationship has been volatile, collapsing in Q2 2025 over compounding practices before resuming. For a detailed look at how telehealth names are being repriced around GLP-1 access, see this recent coverage of GLP-1 telehealth winners.<\/p>\n
HIMS shares are still down 6% year to date, leaving room between the current quote and JPMorgan’s $35 target. Reddit sentiment around Hims & Hers has stayed consistently bullish, with scores of 70 to 82 through April.<\/p>\n
What It Means for Your Portfolio <\/p>\n
The bull case for Hims & Hers stock is straightforward: platform economics, Rest of World revenue growing 825% year over year, and a long-term target of at least $6.5 billion in 2030 revenue. JPMorgan’s Overweight rating validates that runway.<\/p>\n
The bear case deserves equal weight, though. Compounded semaglutide remains under regulatory scrutiny, Hims & Hers’ gross margin compressed roughly 500 basis points to 72%, and the company carries about $1 billion in convertible debt. Securities class actions tied to the original Novo termination also remain unresolved.<\/p>\n
For retirement-focused investors, Hims & Hers stock looks more like a growth allocation than a core holding. Modest position sizing, with room to average in if the Novo Nordisk relationship matures into durable branded GLP-1 distribution, is the prudent way to play this initiation.<\/p>\n
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks <\/p>\n
This analyst’s 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Quick Read JPMorgan initiated Hims & Hers (HIMS) with Overweight and $35 target, citing Novo Nordisk (NVO) partnership…\n","protected":false},"author":2,"featured_media":69740,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[38056,621,15852,272,38057],"class_list":["post-69739","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-cory-carpenter","tag-hims","tag-jpmorgan","tag-novo-nordisk","tag-womens-health"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116478833231190518","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/69739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=69739"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/69739\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/69740"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=69739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=69739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=69739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}